Hepatitis C News

The Louisiana Department of Health selected Asegua Therapeutics, a subsidiary of Gilead Sciences, as their pharmaceutical partner in a “subscription style” payment plan designed to provide state residents with access to hepatitis C treatment, according to a press release from the department.

When it comes to viral hepatitis, hepatitis C has become relatively boring since curative therapies have been so effective in treating the disease.

The U.S. Department of Veterans Affairs announced that it is on track to eliminate hepatitis C in all veterans willing and able to receive treatment within a timeframe of two months, according to a press release from the office.

Twelve weeks of combination Sovaldi and NS5A inhibitors without ribavirin was a reliable therapy with high rates of sustained virologic response for recurrent hepatitis C after liver transplantation, according to a study published in Hepatology.

Kidney transplant recipients with hepatitis B and hepatitis C in whom viral replication was controlled had similar overall and graft survival rates as patients without viral hepatitis, according to data published in Journal of Hepatology.

Long-term surveillance among men who have sex with men with HIV after clearance of hepatitis C may be warranted as reinfection rates remain high and continue to occur more than 11 years after clearance regardless of treatment, according to a study presented at CROI.

The rates of hepatitis C incidence among men who have sex with men with HIV has significantly decreased in London since the epidemic peak in 2015, coinciding with wider access to direct-acting antiviral therapy, according to data presented at CROI.

SEATTLE — A recent analysis found that IV drug use and hepatitis C virus infection were the best predictors of incident syphilis among women with HIV.

All patients who completed direct-acting antiviral therapy after orthotopic heart transplantation with hepatitis C-positive donor hearts achieved sustained virologic, according to results from a recent study.

AbbVie announced an agreement with the pan-Canadian Pharmaceutical Alliance in which Ontario will be first province to reimburse the hepatitis C direct-acting antiviral Maviret on its public formulary as of February 28, 2019, according to a press release.